Application of traditional Chinese medicine composition in preparation of medicine for promoting human body function recovery in novel coronavirus infection recovery period

Abstract

The invention discloses an application of a traditional Chinese medicine composition in preparation of a medicine for promoting human body function recovery in a novel coronavirus infection recovery period. The traditional Chinese medicine composition comprises astragalus membranaceus, pyrola, bighead atractylodes rhizome, poria cocos, codonopsis pilosula, black prepared common monkshood daughter root, dogwood, salvia miltiorrhiza, leonurus, parasitic loranthus, pyrrosia lingua, oldenlandia diffusa and achyranthes bidentata. The traditional Chinese medicine composition can effectively recover the olfactory and gustatory functions of patients suffering from olfactory and gustatory disorders in the recovery period of novel coronavirus infection. In addition, the traditional Chinese medicine composition can also effectively improve the fatigue symptom occurring in the recovery period of novel coronavirus infection and enhance the immunity of a patient in the recovery period of novel coronavirus infection. The traditional Chinese medicine composition disclosed by the invention provides a new choice for developing a medicine for promoting human body function recovery in a novel coronavirus infection recovery period, and has a wide application prospect.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular, to the use of a traditional Chinese medicine composition in the preparation of a medicine for promoting the recovery of human functions during the recovery period of novel coronavirus infection. Background Art

[0002] After being infected with the novel coronavirus, most patients recover after about 10 days of treatment, but some patients will still experience a series of long-term clinical symptoms involving multiple systems and organs in the body after treatment, that is, they enter the recovery period of novel coronavirus infection. Patients in the recovery period of novel coronavirus infection include not only severely hospitalized patients, but also mild and moderate patients and even non-hospitalized patients. The persistence of multi-system symptoms and impaired function greatly affects the long-term quality of life and daily activities of patients.

[0003] Patients recovering from novel coronavirus infection often experience symptoms of loss of smell or taste. Anosmia is often manifested as a decrease or loss of sensitivity to olfactory stimulation. In addition, a small number of patients may also experience symptoms such as runny nose and itchy nose. Anosmia is mainly manifested as the tongue being insensitive to any taste stimulation, having little reaction to extreme tastes, and being unable to distinguish tastes. Due to the lack of taste stimulation, the patient's saliva secretion is reduced, and symptoms such as dry mouth and dry throat appear. Loss of smell and taste is often difficult to recover, causing loss of appetite and even malnutrition in patients recovering from novel coronavirus infection, seriously affecting the patient's quality of life.

[0004] In addition to the loss of smell and taste, patients recovering from novel coronavirus infection often experience fatigue symptoms. Continuous fatigue can reduce patients' attention, energy and vitality, affecting their quality of life. Studies have found that cell typing in patients recovering from novel coronavirus infection showed a decrease in the proportion of T lymphocytes (CD4, CD8), indicating that the patient's body is still in a state of low immune function.

[0005] Some patients have symptoms similar to myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) during recovery from COVID-19, and approximately 13% to 45% of people who experience persistent debilitating symptoms after acute COVID-19 meet the National Academy of Medicine's case definition for ME / CFS. However, while most symptoms of the two diseases are similar, symptoms such as decreased sense of smell and taste, rash, and hair loss, which are common in patients recovering from COVID-19, are rarely reported in ME / CFS patients (PMID: 37342500).

[0006] Due to the diverse clinical symptoms and complex course of the novel coronavirus infection recovery period, it is of great scientific significance and clinical value to explore drugs that specifically promote the recovery of human functions during the recovery period of novel coronavirus infection. The cost of new drug development is high. In recent years, the research strategy of new uses of old drugs has become a hot spot in drug development. The Qilu Yishen Recipe is derived from the clinical prescription of Professor Du Yumao, a nephrologist. It is composed of 13 Chinese medicines, with Astragalus and Deer Stomach as the main medicines to warm the spleen and kidney and remove dampness and turbidity; Atractylodes macrocephala, Poria cocos, Codonopsis pilosula, and Aconite as the ministers, which help the main medicines to strengthen the spleen and warm the kidney, and remove dampness and turbidity; while the adjuvants are Salvia miltiorrhiza and Leonurus japonicus to promote blood circulation and remove blood stasis; Cornus officinalis and Viscum album to nourish the kidney and produce essence; Pyrrosia lutea and Hedyotis diffusa to clear heat and dampness, and restrict the dryness of the medicine. At the same time, Achyranthes bidentata is used as the guiding medicine to lead the medicines into the lower part of the body. These 13 Chinese medicines work together to warm the spleen and kidney yang deficiency and remove dampness and turbidity, and have the characteristics of nourishing without being greasy, warming without being dry, cold, warming and taking both the symptoms and the root into consideration. The Qilu Yishen Tablets made from this recipe are a national Class III new Chinese medicine, clinically used to treat chronic kidney disease. At present, no new use of the Qilu Yishen recipe has been found in promoting the recovery of human function during the recovery period of novel coronavirus infection. Summary of the invention

[0007] In order to overcome the above-mentioned defects and shortcomings in the prior art, the present invention provides an application of a Chinese medicine composition in the preparation of a drug for promoting the recovery of human function during the recovery period of novel coronavirus infection.

[0008] The first object of the present invention is to provide a Chinese medicine composition for use in the preparation of a drug for promoting the recovery of human function during the recovery period of novel coronavirus infection.

[0009] Therefore, the present invention claims the following:

[0010] A Chinese medicine composition is used in the preparation of a drug for promoting the recovery of human function during the recovery period of novel coronavirus infection. The Chinese medicine composition comprises, by weight, 48-52 parts by weight of Astragalus, 28-32 parts by weight of Herba Lycopi, 17-21 parts by weight of Atractylodes macrocephala, 17-21 parts by weight of Poria, 17-21 parts by weight of Codonopsis pilosula, 6-10 parts by weight of Heishun Pian, 13-17 parts by weight of Cornus officinalis, 26-30 parts by weight of Salvia miltiorrhiza, 49-53 parts by weight of Leonurus japonicus, 23-27 parts by weight of Viscum album, 17-21 parts by weight of Pyrrosia sinensis, 40-44 parts by weight of Hedyotis diffusa and 14-18 parts by weight of Achyranthes bidentata.

[0011] Preferably, by weight, the traditional Chinese medicine composition comprises 50 parts by weight of Astragalus, 30 parts by weight of Herba Lycopi, 19 parts by weight of Atractylodes, 19 parts by weight of Poria, 19 parts by weight of Codonopsis, 8 parts by weight of Heishun Pian, 15 parts by weight of Cornus officinalis, 28 parts by weight of Salvia miltiorrhiza, 51 parts by weight of Leonurus japonicus, 25 parts by weight of Viscum album, 19 parts by weight of Pyrrosia, 42 parts by weight of Hedyotis diffusa and 16 parts by weight of Achyranthes bidentata.

[0012] Preferably, the promoting the recovery of human function in the recovery period of novel coronavirus infection is to restore the olfactory function of patients in the recovery period of novel coronavirus infection with olfactory disorder.

[0013] Preferably, the method of promoting the recovery of human function in the recovery period of novel coronavirus infection is to restore the taste function of patients in the recovery period of novel coronavirus infection with taste disorder.

[0014] Preferably, the promoting the recovery of human body functions during the recovery period of novel coronavirus infection is to improve the fatigue symptoms of patients during the recovery period of novel coronavirus infection.

[0015] Preferably, the promoting the recovery of human body functions during the recovery period of novel coronavirus infection is to enhance the immunity of patients during the recovery period of novel coronavirus infection.

[0016] More preferably, the enhancing the immunity of patients in the recovery stage of novel coronavirus infection is to reduce the levels of immunoglobulins IgA, IgM and / or IgG in the body fluids of patients in the recovery stage of novel coronavirus infection.

[0017] More preferably, the enhancing the immunity of patients in the recovery stage of novel coronavirus infection is to reduce the level of complement C3 and / or complement C4 in the body fluids of patients in the recovery stage of novel coronavirus infection.

[0018] More preferably, the enhancing the immunity of patients in the recovery stage of novel coronavirus infection is to increase the percentage of CD3 lymphocytes and / or CD4 lymphocytes in the body fluids of patients in the recovery stage of novel coronavirus infection.

[0019] More preferably, the enhancing the immunity of patients in the recovery stage of novel coronavirus infection is to increase the ratio of CD4 / CD8 lymphocytes in the body fluids of patients in the recovery stage of novel coronavirus infection.

[0020] As an practicable manner, the drug is in the form of solid, semi-solid or liquid.

[0021] As an practicable manner, the dosage form of the drug includes but is not limited to tablets, capsules, granules, pills, powders, and mixtures.

[0022] As an practicable manner, the drug further comprises a pharmaceutically acceptable excipient.

[0023] As an practicable manner, the pharmaceutically acceptable excipients include fillers, surfactants, binders, antioxidants, preservatives, flavoring agents, lubricants, coating agents or coloring agents.

[0024] Compared with the prior art, the present invention has the following beneficial effects:

[0025] The present invention discloses an application of a Chinese medicine composition in the preparation of a drug for promoting the recovery of human function during the recovery period of novel coronavirus infection, wherein the Chinese medicine composition comprises astragalus, herba scutellariae, atractylodes macrocephala, poria, codonopsis pilosula, heishunpian, cornus officinalis, salvia miltiorrhiza, motherwort, mistletoe, pyrrosia, oldenlandia diffusa and achyranthes bidentata. For patients with olfactory and taste disorders during the recovery period of novel coronavirus infection, the Chinese medicine composition can effectively restore their olfactory and taste functions. After taking the Chinese medicine composition of the present invention for 5 to 7 days, 80 to 95% of the patients with olfactory or taste disorders during the recovery period of novel coronavirus infection have their olfactory or taste functions restored.

[0026] In addition, the Chinese medicine composition can also effectively improve the fatigue symptoms that occur during the recovery period of the new coronavirus infection, and enhance the immunity of patients during the recovery period of the new coronavirus infection, which is specifically manifested in reducing the levels of immunoglobulins IgA, IgM, IgG, complement C3 and complement C4 in the body fluids of patients during the recovery period of the new coronavirus infection, and increasing the percentage of CD3 and CD4 lymphocytes and the ratio of CD4 / CD8 lymphocytes in the body fluids of patients during the recovery period of the new coronavirus infection. The Chinese medicine composition of the present invention provides a new choice for the development of drugs to promote the recovery of human functions during the recovery period of the new coronavirus infection, and has broad application prospects. DETAILED DESCRIPTION

[0027] The present invention is further described below with reference to specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0028] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0029] Example 1 A method for preparing a Chinese medicine composition

[0030] Take 50 parts of Astragalus, 30 parts of Herba Lucilii, 19 parts of Atractylodes macrocephala, 19 parts of Poria, 19 parts of Codonopsis pilosula, 8 parts of Radix Aconiti Lateralis Preparata (Heishun Pian), 15 parts of Fructus Corni, 25 parts of Herba Mori Parasiticae, 28 parts of Salvia miltiorrhizae, 51 parts of Herba Leonuri, 19 parts of Pyrrosiae, 42 parts of Herba Hedyotis diffusae, and 16 parts of Radix Achyranthis Bidentatae, soak the medicinal materials in water for 30 minutes, decoct three times, add 7 times, 5 times, and 5 times of water respectively, and decoct for 30 minutes each time. Combine the three medicinal liquids to obtain a Chinese medicine composition.

[0031] Example 2 Preparation method of a Chinese medicine composition

[0032] Take 48 parts of astragalus, 28 parts of gypsum, 17 parts of atractylodes, 17 parts of tuckahoe, 17 parts of codonopsis, 6 parts of processed aconite (black shun tablets), 13 parts of cornus, 23 parts of viburnum, 26 parts of salvia miltiorrhiza, 49 parts of motherwort, 17 parts of pyrrosia, 40 parts of oldenlandia diffusa and 14 parts of achyranthes bidentata, soak the medicinal materials in water for 30 minutes, decoct them three times, add 7 times, 5 times and 5 times of water respectively, decoct for 30 minutes each time, and combine the three medicinal liquids to obtain a traditional Chinese medicine composition.

[0033] Example 3 Preparation method of a Chinese medicine composition

[0034] Take 52 parts of astragalus, 32 parts of gypsum, 21 parts of atractylodes, 21 parts of tuckahoe, 21 parts of codonopsis, 10 parts of processed aconite (black shun tablets), 17 parts of cornus, 27 parts of viburnum, 30 parts of salvia, 53 parts of motherwort, 21 parts of pyrrosia, 44 parts of oldenlandia diffusa and 18 parts of achyranthes, soak the medicinal materials in water for 30 minutes, decoct them three times, add 7 times, 5 times and 5 times of water respectively, decoct for 30 minutes each time, and combine the three medicinal liquids to obtain a traditional Chinese medicine composition.

[0035] Example 4 Chinese medicine composition improves fatigue symptoms during the recovery period of novel coronavirus infection and enhances immunity

[0036] 1. Experimental Methods

[0037] 1. Experimental Grouping

[0038] A randomized controlled trial was used to select patients in the recovery period of novel coronavirus infection who were receiving rehabilitation treatment. A total of 80 patients who met the research criteria were included and randomly divided into three experimental groups and one control group.

[0039] Patient inclusion criteria: patients in the recovery period of novel coronavirus infection; body temperature returns to normal for more than 3 days; aged 18 to 65 years, regardless of gender.

[0040] Exclusion criteria: patients with mental illness, limited cognitive ability and disabilities stipulated by law; patients with severe primary heart, liver, kidney, blood or other diseases that affect their survival; pregnant or lactating women; patients with known allergies to the trial drugs; patients who have participated in or are participating in other drug clinical trials within 1 month.

[0041] 2. Method of administration

[0042] The patients in the control group were only given conventional treatment, and the patients in experimental groups 1 to 3 were additionally given the Chinese medicine composition prepared in Examples 1 to 3 on the basis of conventional treatment, twice a day, 200 mL each, for 4 consecutive weeks.

[0043] Conventional treatment includes home health education, drug support therapy and psychological intervention. Home health education includes: home activity suggestions, dietary suggestions, and personal protection suggestions. Drug support therapy means: for patients with underlying diseases such as hypertension, diabetes, dyslipidemia, etc., corresponding drug treatment is given according to the specific conditions of the patients. For patients with psychological dysfunction, psychological rehabilitation treatment is given in a timely manner, including mindfulness relaxation and cognitive behavioral therapy, etc.

[0044] 3. Efficacy observation indicators

[0045] (1) Fatigue status evaluation

[0046] The Chalder Fatigue Scale (CFQ-11) was used to assess the fatigue of the two groups of patients before and after medication. The scale included physical fatigue (1-7 questions) and psychological fatigue (8-11 questions). Question 11 was reverse scored (i.e., 0 points for yes and 1 point for no), and the other questions were forward scored (i.e., 1 point for yes and 0 points for no). There were 11 items in total. All items adopted a two-level scoring method of 0 to 1 point. The total score ranged from 0 to 11 points. A score of ≥4 points was considered to meet the fatigue criteria. The higher the score, the more severe the fatigue.

[0047] (2) Immune function

[0048] Venous blood was drawn from the two groups of patients on an empty stomach in the morning before and after administration, and the changes of peripheral T lymphocyte subsets (CD3, CD4, CD8) were detected by flow cytometry. The changes of peripheral humoral immunity-related indicators (IgA, IgM, IgG, complement C3, complement C4) of the two groups of patients were detected by blood biochemical analyzer.

[0049] (3) Changes in other clinical symptoms: The presence or absence of clinical symptoms in the two groups of patients before and after medication was recorded (statistical items include: insomnia, anxiety, chest tightness, muscle aches, joint pain, palpitations, indigestion, dizziness, chest pain, hand numbness, cough, shortness of breath after activity, hair loss and other symptoms).

[0050] (4) Safety evaluation: Vital signs: blood pressure, heart rate, respiratory rate, body temperature; Laboratory tests: blood routine, liver function, kidney function; Adverse reactions: Digestive system discomfort such as abdominal distension, abdominal pain, diarrhea, belching, nausea, vomiting, etc.; Skin allergic reactions such as skin rash, itching, local flushing, etc.; Other discomforts such as dizziness, headache, and increased heart rate.

[0051] 4. Data Analysis

[0052] Statistical analysis was performed using Prism 10 software, and the results were analyzed by t-test for inter-group testing. Data are expressed as mean ± standard deviation, and P < 0.05 was considered significant.

[0053] 2. Experimental Results

[0054] The results of fatigue are shown in Table 1. Compared with before administration, the CFQ-11 fatigue scores of Experimental Groups 1 to 3 were significantly reduced after taking the Chinese medicine composition prepared in Examples 1 to 3 for 2 and 4 weeks (P<0.05); compared with the control group, the CFQ-11 fatigue scores of Experimental Groups 1 to 3 were significantly reduced after 2 and 4 weeks of administration (P<0.05); compared with Experimental Group 1 at the same time point, there was no significant difference in CFQ-11 fatigue scores between Experimental Groups 2 and 3 (P>0.05).

[0055] Table 1 Comparison of CFQ-11 scale scores before and after medication (mean ± SD)

[0056] Grouping Number of cases Before administration 2 weeks after administration 4 weeks after administration Experimental Group 1 20 8.3±2.4 <![CDATA[6.2±1.5 *# ]]> <![CDATA[3.1±0.6 *# ]]> Experimental Group 2 20 8.1±2.0 <![CDATA[6.0±1.7 *# ]]> <![CDATA[3.0±0.5 *# ]]> Experimental Group 3 20 8.4±2.2 <![CDATA[6.5±1.3 *# ]]> <![CDATA[3.4±0.7 *# <!-- 4 -->]]> Control group 20 8.6±2.1 8.1±1.8 6.3±1.1

[0057] Note: Compared with before administration, ** P<0.01, * P<0.05; compared with the control group at the same time point, ## P<0.01, # P<0.05.

[0058] The changes in humoral immunity-related indicators are shown in Table 2. Compared with before administration, after taking the Chinese medicine composition prepared by Examples 1 to 3 for 2 and 4 weeks, the levels of immunoglobulins IgA, IgM, IgG, and complement C3 and C4 in Experimental Groups 1 to 3 were significantly decreased (P<0.05); compared with the control group, after administration for 2 and 4 weeks, the levels of immunoglobulins IgA, IgM, IgG, and complement C3 and C4 in Experimental Groups 1 to 3 were significantly decreased (P<0.05); compared with Experimental Group 1 at the same time point, there were no significant differences in the levels of immunoglobulins IgA, IgM, IgG, and complement C3 and C4 in Experimental Groups 2 and 3 (P>0.05).

[0059] Table 2 Changes in humoral immunity related indicators (mean±SD, n=20, g / L)

[0060]

[0061] Note: Compared with before administration, ** P<0.01, * P<0.05; compared with the control group at the same time point, ## P<0.01, # P<0.05.

[0062] Compared with before administration, after taking the Chinese medicine composition prepared by Examples 1 to 3 for 2 and 4 weeks, the CD3, CD4 percentages and CD4 / CD8 ratios of Experimental Groups 1 to 3 were significantly increased (P<0.05); compared with the control group, after administration for 2 and 4 weeks, the CD3, CD4 percentages and CD4 / CD8 ratios of the experimental group were significantly increased (P<0.05); compared with Experimental Group 1 at the same time point, there were no significant differences in the CD3, CD4 percentages and CD4 / CD8 ratios between Experimental Groups 2 and 3 (P>0.05).

[0063] Table 3 Changes of T lymphocyte subsets before and after administration (mean ± SD, n = 20)

[0064]

[0065]

[0066] Note: Compared with before administration, ** P<0.01, * P<0.05; compared with the control group at the same time point, ## P<0.01, # P<0.05.

[0067] After taking the traditional Chinese medicine composition prepared in Examples 1 to 3, the number of patients in the recovery period of novel coronavirus infection with insomnia, anxiety, chest tightness, muscle aches, joint pains, palpitations, indigestion, dizziness, chest pain, numbness of hands, coughs and other symptoms was significantly less than that in the control group.

[0068] During this study, the vital signs of the four groups of patients were stable. There were no abnormalities in the blood routine, liver function, and kidney function of the four groups of patients before and after medication, and no adverse reactions related to traditional Chinese medicine were observed.

[0069] Example 5 Chinese medicine composition improves olfactory dysfunction during the recovery period of novel coronavirus infection

[0070] 1. Experimental Methods

[0071] A randomized controlled trial was used to enroll 40 patients with olfactory impairment in the recovery period of novel coronavirus infection who were receiving rehabilitation treatment and randomly divided into an experimental group and a control group, with 20 cases in each group. The control group was given only conventional treatment, and the experimental group was given the Chinese medicine composition prepared in Example 1 on the basis of conventional treatment, twice a day, 200 mL per dose. Conventional treatment was the same as in Example 4, including home health education, drug support therapy and psychological intervention.

[0072] The olfactory function was tested by the Sniffin Sticks test. The evaluation criteria for olfactory function were as follows: 48-31 points: normal olfactory function; 30-16 points: decreased olfactory function; ≤15 points: loss of olfactory function. Drug efficacy (%) = number of people with 48-31 points / total number of people. Data were calculated using the χ 2 P<0.05 was considered significant.

[0073] 2. Experimental Results

[0074] The results are shown in Table 4. On the first day after taking the Chinese medicine composition prepared in Example 1, 25% of the patients with olfactory impairment in the convalescent period of novel coronavirus infection recovered their sense of smell; after taking it for 5 days, 80% of the patients with olfactory impairment in the convalescent period of novel coronavirus infection recovered their sense of smell; after taking it for 7 days, 95% of the patients with olfactory impairment in the convalescent period of novel coronavirus infection recovered their sense of smell. This shows that the Chinese medicine composition prepared in Example 1 has a strong ability to restore the olfactory function of patients with olfactory impairment in the convalescent period of novel coronavirus infection.

[0075] Table 4 Recovery of patients' sense of smell before and after administration (unit: person)

[0076]

[0077]

[0078] Note: Compared with the control group at the same time point, * P<0.05, ** P<0.01.

[0079] The Chinese medicine compositions prepared in Examples 2 and 3 have similar effects to the Chinese medicine composition prepared in Example 1 in improving olfactory disorders occurring during the recovery period of novel coronavirus infection.

[0080] Example 6 Chinese medicine composition improves taste disturbance during the recovery period of novel coronavirus infection

[0081] 1. Experimental Methods

[0082] A randomized controlled trial was used to enroll 40 patients with novel coronavirus infection recovery period who were receiving rehabilitation treatment and had taste disorders. They were randomly divided into an experimental group and a control group, with 20 cases in each group. The control group was given only conventional treatment, and the experimental group was given the Chinese medicine composition prepared in Example 1 on the basis of conventional treatment, twice a day, 200 mL per dose. Conventional treatment was the same as in Example 4, including home health education, drug support therapy and psychological intervention.

[0083] The taste function was tested using the Chinese version of the chemotherapy-induced taste alternation scale (CiTAS, with a total score of 90 points, a total score ≤ 18 points indicating no taste change, a total score > 18 points indicating taste change, and the higher the score, the more severe the taste change).

[0084] The taste function evaluation criteria of this experiment are as follows: ≤18 points: normal taste function; 19-54 points: decreased taste function; 55-90 points: loss of taste function. 2 P<0.05 was considered significant.

[0085] 2. Experimental Results

[0086] The results are shown in Table 5. On the first day after taking the Chinese medicine composition prepared in Example 1, 25% of the patients with taste disorders in the recovery period of novel coronavirus infection had their taste restored. After taking it for 5 days, 80% of the patients with taste disorders in the recovery period of novel coronavirus infection had their taste restored, and after taking it for 7 days, 95% of the patients with taste disorders in the recovery period of novel coronavirus infection had their taste restored. This shows that the Chinese medicine composition prepared in Example 1 has a strong ability to restore the taste function of patients with taste disorders in the recovery period of novel coronavirus infection.

[0087] Table 5 Recovery of patients' sense of taste before and after administration (unit: person)

[0088]

[0089] Note: Compared with the control group at the same time point, * P<0.05, ** P<0.01.

[0090] The Chinese medicine compositions prepared in Examples 2 and 3 have similar effects to the Chinese medicine composition prepared in Example 1 in improving taste disorders caused by the recovery period of novel coronavirus infection.

[0091] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. Use of a Chinese medicine composition in the preparation of a drug for promoting the recovery of human function during the recovery period of novel coronavirus infection, characterized in that: By weight, the traditional Chinese medicine composition comprises 48-52 parts by weight of Astragalus, 28-32 parts by weight of Herba Lycopi, 17-21 parts by weight of Atractylodes, 17-21 parts by weight of Poria, 17-21 parts by weight of Codonopsis, 6-10 parts by weight of Heishun Pian, 13-17 parts by weight of Cornus officinalis, 26-30 parts by weight of Salvia miltiorrhiza, 49-53 parts by weight of Leonurus japonicus, 23-27 parts by weight of Viscum album, 17-21 parts by weight of Pyrrosia, 40-44 parts by weight of Oldenlandia diffusa and 14-18 parts by weight of Achyranthes bidentata.

2. The use according to claim 1, characterized in that: By weight, the traditional Chinese medicine composition comprises 50 parts by weight of Astragalus, 30 parts by weight of Herba Lycopi, 19 parts by weight of Atractylodes, 19 parts by weight of Poria, 19 parts by weight of Codonopsis, 8 parts by weight of Heishun Pian, 15 parts by weight of Cornus officinalis, 28 parts by weight of Salvia miltiorrhiza, 51 parts by weight of Leonurus japonicus, 25 parts by weight of Viscum album, 19 parts by weight of Pyrrosia sinensis, 42 parts by weight of Hedyotis diffusa and 16 parts by weight of Achyranthes bidentata.

3. The use according to claim 1, characterized in that: The promoting of the recovery of human functions in the recovery period of novel coronavirus infection is to restore the olfactory function of patients in the recovery period of novel coronavirus infection with olfactory impairment.

4. The use according to claim 1, characterized in that: The method of promoting the recovery of human functions in the recovery period of novel coronavirus infection is to restore the taste function of patients in the recovery period of novel coronavirus infection with taste disorder.

5. The use according to claim 1, characterized in that: The promoting of the recovery of human functions during the recovery period of novel coronavirus infection is to improve the fatigue symptoms of patients during the recovery period of novel coronavirus infection.

6. The use according to claim 1, characterized in that: The promoting of the recovery of human body functions during the recovery period of novel coronavirus infection is to enhance the immunity of patients during the recovery period of novel coronavirus infection.

7. The use according to claim 1, characterized in that: The drug is in the form of solid, semisolid or liquid.

8. The use according to claim 1, characterized in that: The dosage form of the drug includes but is not limited to tablets, capsules, granules, pills, powders, and mixtures.

9. The use according to claim 1, characterized in that: The drug also includes pharmaceutically acceptable excipients.

10. The use according to claim 1, characterized in that: The pharmaceutically acceptable excipients include fillers, surfactants, binders, antioxidants, preservatives, flavoring agents, lubricants, coating agents or coloring agents.

Images